© 2024 MJH Life Sciences™ and Center for Biosimilars®. All rights reserved.
Latest Conference Articles
Part 2: Kolodziej Discusses Biosimilar Support at NCCN Conference
Skylar Jeremias
June 11 2020
NCCN Virtual Annual Conference
Although biosimilar uptake has been slow in the United States, the current administration has enacted several policies to help speed up the process, according to Michael Kolodziej, MD, who presented at the National Comprehensive Cancer Network (NCCN) 2020 Virtual Conference.
Batch Variation in Trastuzumab Study Affects Outcomes
Tony Hagen
June 8 2020
Downward “drift” in batches of reference trastuzumab shed more light on the importance of antibody-dependent cell-mediated cytotoxicity on survival, investigators reported at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.
More Savings Are Possible for Oncology Care Model, ASCO Study Says
Tony Hagen
June 2 2020
A real-world study helped show how pegfilgrastim biosimilar can improve savings in the Oncology Care Model and its successor, the Oncology Care First Model, according to findings presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology.
Biosimilar Pegfilgrastim Savings Aid More Patients in Models Presented at ASCO
Skylar Jeremias
June 1 2020
Switching patients with cancer to biosimilar pegfilgrastim for prophylaxis treatment of chemotherapy-induced febrile neutropenia could generate significant savings for adjuvant treatment, investigators found in studies presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).
Filgrastim Agent Is Cost-Effective in NSCLC, According to ASCO Study
Skylar Jeremias
May 31 2020
When used as a primary prophylaxis, biosimilar filgrastim (Zarxio) was found to be cost-effective when used to treat patients with nonmetastatic non–small cell lung cancer (NSCLC), according to a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).
Rituximab Biosimilar Demonstrates Similarity in ASCO Study
Tony Hagen
May 31 2020
The rituximab biosimilar candidate ABP 798 met primary and secondary end points for safety, efficacy, and immunogenicity in a study presented at ASCO20 Virtual, the annual meeting of the American Society of Clinical Oncology (ASCO).